Condition: NSCLC · Sponsor: Peking Union Medical College
This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.
This description comes directly from the study's public registry record.
Li Junling doctor · +86 13801178891 · lijunling@cicams.ac.cn
Always discuss trial participation with your own doctor first.
| cancer hospital， Chinese Academy of medical sciences and Peking union medical college | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07247227